glycosylated, this sialylated recombinant form would have a short circulatory life (the carbohydrates are not relevant to the inhibitor function). Therefore, C1-inhibitor has also been produced in glycosylated form using transgenic rabbits. This form of recombinant C1-inhibitor also has been given orphan drug status for delayed graft function following organ transplantation and for capillary leakage syndrome. References Further reading External links The MEROPS online database for peptidases and their inhibitors: I04.024 Complement system Serine protease inhibitors Takeda Pharmaceutical Company brands